Dynamic Technology Lab Private Ltd Makes New $910,000 Investment in Vericel Co. (NASDAQ:VCEL)

Dynamic Technology Lab Private Ltd purchased a new position in shares of Vericel Co. (NASDAQ:VCEL) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 21,544 shares of the biotechnology company’s stock, valued at approximately $910,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Nisa Investment Advisors LLC boosted its position in shares of Vericel by 9.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 220 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares in the last quarter. PFG Investments LLC grew its stake in shares of Vericel by 6.2% in the 2nd quarter. PFG Investments LLC now owns 6,850 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 400 shares during the period. Farther Finance Advisors LLC lifted its position in shares of Vericel by 48.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after buying an additional 405 shares during the period. Finally, Arizona State Retirement System boosted its stake in Vericel by 3.3% in the 2nd quarter. Arizona State Retirement System now owns 12,866 shares of the biotechnology company’s stock valued at $590,000 after buying an additional 406 shares in the last quarter.

Insider Transactions at Vericel

In other news, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at $9,142,373.06. This trade represents a 7.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the completion of the sale, the director now owns 11,000 shares of the company’s stock, valued at $443,850. This represents a 34.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 31,666 shares of company stock worth $1,350,764 in the last quarter. 7.20% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

VCEL has been the subject of a number of analyst reports. Canaccord Genuity Group reissued a “buy” rating and set a $60.00 price objective on shares of Vericel in a report on Tuesday, November 19th. StockNews.com raised shares of Vericel from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Canaccord Genuity Group initiated coverage on Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Vericel in a report on Friday, November 8th. Finally, BTIG Research boosted their price objective on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a research note on Tuesday. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $59.71.

Vericel Stock Performance

NASDAQ VCEL opened at $57.76 on Thursday. Vericel Co. has a 52 week low of $32.31 and a 52 week high of $61.49. The stock has a market capitalization of $2.85 billion, a P/E ratio of 962.83 and a beta of 1.66. The stock has a fifty day moving average of $46.92 and a 200-day moving average of $47.22.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.03. The firm had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. Vericel had a return on equity of 1.48% and a net margin of 1.56%. Equities research analysts forecast that Vericel Co. will post 0.13 earnings per share for the current fiscal year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.